SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

[July 04, 2014]

Research and Markets: Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/fpztpk/opportunityanalyze) has announced the addition of the "Opportunity Analyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018" report to their offering.

Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled proliferation of B lymphocytes (a type of white blood cell) in the bone marrow, blood and lymphoid tissues. This report focuses on the current treatment landscape, unmet needs, pipeline and commercial opportunity in the CLL market with coverage of both the first-line and relapsed/refractory settings.

While the current standard of care consists of chemoimmunotherapy, CLL disease management is poised for dramatic changes, particularly in the treatment of relapsed/refractory and elderly patients, as four new drugs (Gazyva, Imbruvica, idelalisib and IPI-145) will launch during the forecast period.


Key Questions Answered

  • Which CLL patients have the greatest unmet needs and how well will these needs be addressed by the new agents?
  • How will CLL disease management change as new agents enter the market?
  • What are the R&D and clinical trial design strategies pursued by companies in the CLL space?
  • What are the most promising late-stage pipeline agents for CLL? How do their clinical and commercial attributes compare to one another and the current standards of care?
  • What opportunities will remain for future players following the launch of these pipeline agents?
  • What exciting, innovative approaches are being investigated in the early-stage CLL pipeline?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Disease Management

5 Epidemiology

6 Current Treatment Options

7 Unmet Needs Assessment and Oppportunity Analysis

8 R&D Strategies

9 Pipeline Assessment

10 Pipeline Valuation Analysis

11 Appendix

For more information visit http://www.researchandmarkets.com/research/fpztpk/opportunityanalyze


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.